Samsung Bioepis secures 10-year exclusive drug supply deal in Brazil

Samsung Bioepis has secured a 10-year exclusive deal to supply a rare disease treatment, SB12, to Brazil's Ministry of Health. This agreement strengthens the company's position in Brazil, the largest pharmaceutical market in Latin America, and marks a significant partnership with the Brazilian government. The deal is significant for markets as it demonstrates Samsung Bioepis's growing presence in the global pharmaceutical industry, particularly in emerging markets. This partnership could have long-term implications for the company's growth and influence in the region.

Why it matters

Samsung Bioepis has secured a decade-long exclusive supply deal for a rare disease treatment in Brazil. This deal strengthens its position in Latin America's largest pharmaceutical market and is expected to boost its revenue and market share.

Market impact

Markets & countries in focus

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to The Korea Times. For information only — not financial advice.